These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Preprints are manuscripts made publicly available before they have been submitted for formal peer review and publication. They might contain new research findings or data. Preprints can be a draft or final version of an author's research but must not have been accepted for publication at the time of submission.
submitted on 16.04.2020 and posted on 21.04.2020by Rodrigo Vieira, Harrson Santana, João Silva Jr., Paula Meira, Gabriel Bressan, Osvaldir Pereira Taranto, Paulo Calvo, Mauri Palma
use of microreactors in chemical and pharmaceutical industries allow a series
of advantages due to their reduced sizes regarding conventional batch reactors.
In the present paper the transposition of the reaction between 2,4-Thiazolidinedione
with p-Methoxybenzaldehyde, generating the compound with potential biological
action against diabetes mellitus type II, from batch to a continuous capillary microreactor
was carried out. The microdevice performance was evaluated experimentally and
numerically by Computational Fluid Dynamics. The efficiency and viability of microreactors usage for
the intermediate pharmaceutical active production was assessed. The optimized
operating conditions were obtained for the batch reactor (processing time) and
microreactor (residence time), the promoter base selection and optimal
concentration was also performed, in order to maximize reactants conversion and
reaction yield. Considering the acquired data, computational fluid dynamic simulations were carried out, allowing obtaining a computational methodology to be used for a fast increment of production from microreactor to industrial demand.